256 related articles for article (PubMed ID: 36046389)
1. Circulating biomarkers in malignant pleural mesothelioma.
Viscardi G; Di Natale D; Fasano M; Brambilla M; Lobefaro R; De Toma A; Galli G
Explor Target Antitumor Ther; 2020; 1(6):434-451. PubMed ID: 36046389
[TBL] [Abstract][Full Text] [Related]
2. A liquid biopsy for detecting circulating mesothelial precursor cells: A new biomarker for diagnosis and prognosis in mesothelioma.
Duong BTV; Wu L; Green BJ; Bavaghar-Zaeimi F; Wang Z; Labib M; Zhou Y; Cantu FJP; Jeganathan T; Popescu S; Pantea J; de Perrot M; Kelley SO
EBioMedicine; 2020 Nov; 61():103031. PubMed ID: 33045471
[TBL] [Abstract][Full Text] [Related]
3. Liquid Biopsy in Malignant Pleural Mesothelioma: State of the Art, Pitfalls, and Perspectives.
Cavallari I; Urso L; Sharova E; Pasello G; Ciminale V
Front Oncol; 2019; 9():740. PubMed ID: 31475103
[TBL] [Abstract][Full Text] [Related]
4. Utility of osteopontin and serum mesothelin in malignant pleural mesothelioma diagnosis and prognosis assessment.
Grigoriu BD; Scherpereel A; Devos P; Chahine B; Letourneux M; Lebailly P; Grégoire M; Porte H; Copin MC; Lassalle P
Clin Cancer Res; 2007 May; 13(10):2928-35. PubMed ID: 17504993
[TBL] [Abstract][Full Text] [Related]
5. The established and future biomarkers of malignant pleural mesothelioma.
Panou V; Vyberg M; Weinreich UM; Meristoudis C; Falkmer UG; Røe OD
Cancer Treat Rev; 2015 Jun; 41(6):486-95. PubMed ID: 25979846
[TBL] [Abstract][Full Text] [Related]
6. Multiplex Soluble Biomarker Analysis from Pleural Effusion.
Javadi J; Dobra K; Hjerpe A
Biomolecules; 2020 Jul; 10(8):. PubMed ID: 32731396
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of New Biomarkers in the Prediction of Malignant Mesothelioma in Subjects with Environmental Asbestos Exposure.
Demir M; Kaya H; Taylan M; Ekinci A; Yılmaz S; Teke F; Sezgi C; Tanrikulu AC; Meteroglu F; Senyigit A
Lung; 2016 Jun; 194(3):409-17. PubMed ID: 27032653
[TBL] [Abstract][Full Text] [Related]
8. Significance of serum mesothelin in an asbestos-exposed population in the Czech Republic.
Jakubec P; Pelclova D; Smolkova P; Kolek V; Nakladalova M
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2015 Sep; 159(3):472-9. PubMed ID: 24781044
[TBL] [Abstract][Full Text] [Related]
9. Circulating Epigenetic Biomarkers in Malignant Pleural Mesothelioma: State of the Art and critical Evaluation.
Ferrari L; Carugno M; Mensi C; Pesatori AC
Front Oncol; 2020; 10():445. PubMed ID: 32318342
[TBL] [Abstract][Full Text] [Related]
10. Peripheral Blood DNA Methylation as Potential Biomarker of Malignant Pleural Mesothelioma in Asbestos-Exposed Subjects.
Guarrera S; Viberti C; Cugliari G; Allione A; Casalone E; Betti M; Ferrante D; Aspesi A; Casadio C; Grosso F; Libener R; Piccolini E; Mirabelli D; Dianzani I; Magnani C; Matullo G
J Thorac Oncol; 2019 Mar; 14(3):527-539. PubMed ID: 30408567
[TBL] [Abstract][Full Text] [Related]
11. Combination of mesothelin and CEA significantly improves the differentiation between malignant pleural mesothelioma, benign asbestos disease, and lung cancer.
Muley T; Dienemann H; Herth FJ; Thomas M; Meister M; Schneider J
J Thorac Oncol; 2013 Jul; 8(7):947-51. PubMed ID: 23777840
[TBL] [Abstract][Full Text] [Related]
12. Clinical significance of pleural effusion mesothelin in malignant pleural mesothelioma.
Yamada S; Tabata C; Tabata R; Fukuoka K; Nakano T
Clin Chem Lab Med; 2011 Oct; 49(10):1721-6. PubMed ID: 21692685
[TBL] [Abstract][Full Text] [Related]
13. Circulating microRNAs found dysregulated in ex-exposed asbestos workers and pleural mesothelioma patients as potential new biomarkers.
Bononi I; Comar M; Puozzo A; Stendardo M; Boschetto P; Orecchia S; Libener R; Guaschino R; Pietrobon S; Ferracin M; Negrini M; Martini F; Bovenzi M; Tognon M
Oncotarget; 2016 Dec; 7(50):82700-82711. PubMed ID: 27716620
[TBL] [Abstract][Full Text] [Related]
14. Artichoke phytocomplex modulates serum microRNAs in patients exposed to asbestos: a first step of a phase II clinical trial.
Muti P; Sacconi A; Pulito C; Orlandi G; Donzelli S; Morrone A; Jiulian J; Cox GP; Kolb M; Pond G; Kavsak P; Levine MN; Blandino G; Strano S
J Exp Clin Cancer Res; 2022 Aug; 41(1):255. PubMed ID: 35987988
[TBL] [Abstract][Full Text] [Related]
15. Clinical significance of serum vascular endothelial growth factor in malignant pleural mesothelioma.
Yasumitsu A; Tabata C; Tabata R; Hirayama N; Murakami A; Yamada S; Terada T; Iida S; Tamura K; Fukuoka K; Kuribayashi K; Nakano T
J Thorac Oncol; 2010 Apr; 5(4):479-83. PubMed ID: 20357617
[TBL] [Abstract][Full Text] [Related]
16. Soluble mesothelin-related peptide level elevation in mesothelioma serum and pleural effusions.
Pass HI; Wali A; Tang N; Ivanova A; Ivanov S; Harbut M; Carbone M; Allard J
Ann Thorac Surg; 2008 Jan; 85(1):265-72; discussion 272. PubMed ID: 18154821
[TBL] [Abstract][Full Text] [Related]
17. Biomarkers for malignant pleural mesothelioma: current status.
Greillier L; Baas P; Welch JJ; Hasan B; Passioukov A
Mol Diagn Ther; 2008; 12(6):375-90. PubMed ID: 19035624
[TBL] [Abstract][Full Text] [Related]
18. MicroRNA-98 is a prognostic factor for asbestos-induced mesothelioma.
Kim K; Ko Y; Oh H; Ha M; Kang J; Kwon EJ; Kang JW; Kim Y; Heo HJ; Kim G; Kim JW; Kim YH
J Toxicol Environ Health A; 2020 Feb; 83(3):126-134. PubMed ID: 32114955
[TBL] [Abstract][Full Text] [Related]
19. Detection of TGF-β in pleural effusions for diagnosis and prognostic stratification of malignant pleural mesothelioma.
Stockhammer P; Ploenes T; Theegarten D; Schuler M; Maier S; Aigner C; Hegedus B
Lung Cancer; 2020 Jan; 139():124-132. PubMed ID: 31778960
[TBL] [Abstract][Full Text] [Related]
20. HMGB1 and Its Hyperacetylated Isoform are Sensitive and Specific Serum Biomarkers to Detect Asbestos Exposure and to Identify Mesothelioma Patients.
Napolitano A; Antoine DJ; Pellegrini L; Baumann F; Pagano I; Pastorino S; Goparaju CM; Prokrym K; Canino C; Pass HI; Carbone M; Yang H
Clin Cancer Res; 2016 Jun; 22(12):3087-96. PubMed ID: 26733616
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
